NASDAQ:CRSP

CRISPR Therapeutics Q1 2025 Earnings Results & Report

CRISPR Therapeutics logo
$40.19 +0.04 (+0.10%)
Closing price 04:00 PM Eastern
Extended Trading
$40.78 +0.59 (+1.47%)
As of 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CRISPR Therapeutics missed analyst earnings expectations in its Q1 2025 results, released May 6, 2025. The company reported EPS of -$1.58 versus the -$1.27 consensus estimate. Revenue increased 71.6% year over year.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
After Market Closes
Conference Call
12:30 PM ET

CRISPR Therapeutics EPS Results

Actual EPS
-$1.58
Consensus EPS
-$1.27
Beat/Miss
Missed by -$0.31
One Year Ago EPS
-$1.43
EPS Beat Rate
4 of last 8 quarters

CRISPR Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
+71.60%

CRISPR Therapeutics Q1 2025 Earnings FAQ

CRISPR Therapeutics (NASDAQ:CRSP) reported earnings of -$1.58 per share for Q1 2025, missing the consensus estimate of -$1.27. The report was announced on Tuesday, May 6, 2025.

CRISPR Therapeutics Earnings Headlines

ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More CRISPR Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CRISPR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your email.

About CRISPR Therapeutics

CRISPR Therapeutics (NASDAQ:CRSP) is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts.

Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval. The companies share responsibilities for developing and commercializing Casgevy in authorized markets.

Beyond Casgevy, CRISPR Therapeutics is advancing research programs in areas including cancer, autoimmune disease and in vivo gene editing. The company is led by CEO Samarth Kulkarni.

View CRISPR Therapeutics Profile